• CAR T Cells and Immunotherapy in Mantle Cell Lymphoma: Bridging Therapy, Toxicities, and Bispecific Antibodies

  • Mar 30 2023
  • Length: 24 mins
  • Podcast

CAR T Cells and Immunotherapy in Mantle Cell Lymphoma: Bridging Therapy, Toxicities, and Bispecific Antibodies cover art

CAR T Cells and Immunotherapy in Mantle Cell Lymphoma: Bridging Therapy, Toxicities, and Bispecific Antibodies

Listen for free

View show details

  • Summary

  • Drs Peter Martin and Michael Wang discuss the role of CAR T cells in mantle cell lymphoma, how they are used with respect to bridging therapy, and the surveillance and management of toxicities.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/982891). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Mantle Cell Lymphoma https://emedicine.medscape.com/article/203085-overview

    KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/32242358/

    Three-Year Follow-up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study https://pubmed.ncbi.nlm.nih.gov/35658525/

    Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience From the US Lymphoma CAR T Consortium https://ashpublications.org/blood/article/138/Supplement%201/744/479986/Brexucabtagene-Autoleucel-for-Relapsed-Refractory

    Real-World Evidence of Brexucabtagene Autoleucel for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/35271707/

    Frequency of Gastrointestinal Involvement and Its Clinical Significance in Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/12548600/

    Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Effector Cell-Related Adverse Events https://pubmed.ncbi.nlm.nih.gov/33335028/

    Management of a Patient With Mantle Cell Lymphoma Who Developed Severe Neurotoxicity After Chimeric Antigen Receptor T-cell Therapy in ZUMA-2 https://pubmed.ncbi.nlm.nih.gov/33067318/

    Experiences With Glofitamab Administration Following CAR T Therapy in Patients With Relapsed Mantle Cell Lymphoma https://pubmed.ncbi.nlm.nih.gov/36078155/

    Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma https://ash.confex.com/ash/2022/webprogram/Paper157777.html

    GEN3013, Epcoritamab Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma EPCORE™ NHL-1 https://www.clinicaltrials.gov/ct2/show/NCT03625037
    Show More Show Less
Show More Show Less

What listeners say about CAR T Cells and Immunotherapy in Mantle Cell Lymphoma: Bridging Therapy, Toxicities, and Bispecific Antibodies

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.